Sveriges mest populära poddar
The Effective Statistician - in association with PSI
VetenskapNaturvetenskap

Early Development and The Dose Selection in the Immune-oncology

19 min•16 december 2024
Interview with Teppo Huttunen

Key points:

  • Dose Selection Challenge
  • Limitations of 3+3 Design
  • BOIN Design
  • Backfilling
  • Efficacy vs. Safety
  • Statisticians’ Role
  • Practical Challenges
  • FDA Guidance
  • Cross-Functional Approach
  • Industry Trends
  • Cost & Timeline Estimation

Understanding dose selection in immune-oncology is crucial for developing safer and more effective treatments, and statisticians play a central role in driving these decisions.

In this episode, Teppo shares practical insights into overcoming the limitations of traditional methods and adopting more flexible approaches like the BOIN design.

If you want to stay ahead in oncology research and learn how to balance safety, efficacy, and practical challenges in dose optimization, this episode is a must-listen!

Fler avsnitt av The Effective Statistician - in association with PSI

Visa alla avsnitt av The Effective Statistician - in association with PSI
How Applied Improvisation Develops and Reinforces Interpersonal Skills
•33 min
What does a clinical lead expect from a statistician?
•32 min
Measuring Trust – A Key to Effective Leadership
•28 min
Choosing and Interpreting PROs and COAs – A Guide for Clinical Trial Statisticians
•41 min
How Statisticians Can Build Trust and Lead with Emotional Intelligence
•39 min
The Evolving Role of Generative AI in Pharma
•33 min
Kicking Off 2026: Gratitude and What’s Ahead
•2 min
Why to present better and how as a statistician
•36 min
External control arms - how to get to a good one
•27 min
Top 9: Non-parametric analyses - much more than just the Wilcoxon test!
•40 min

The Effective Statistician - in association with PSI med Alexander Schacht and Benjamin Piske, biometricians, statisticians and leaders in the pharma industry finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.